Skip to content

Dr. Herbert Loong

271
Dr. Herbert Loong
龍浩鋒
Share
qualifications
MBBS(HK), PDipMDPath(HK), MRCP(UK), FHKCP, FHKAM(Medicine)
rank
Associate Professor (Clinical) – Department of Clinical Oncology
Deputy Medical Director – Phase 1 Clinical Trials Centre
orcid
0000-0002-6607-1106
email
h_loong@clo.cuhk.edu.hk

Specific Research / Sites of Interest


  1. Sarcoma Medical Oncology

  2. Neuro-oncology

  3. Thoracic Oncology

  4. Melanoma

  5. Experimental Therapeutics / Early Phase Clinical Trials

  6. Cost-Effective Analyses & Health Economics

Short Biography

Dr. Herbert Loong is a Clinical Associate Professor in the Department of Clinical Oncology, and the Deputy Medical Director of the Phase 1 Clinical Trials Centre, at The Chinese University of Hong Kong. He is also the founder of the Prince of Wales Hospital Adult Sarcoma Multidisciplinary Team.

Dr. Loong has received the European Cancer Congress Fellowship Grant (2013), the American Society of Clinical Oncology (ASCO) Annual Meeting Merit Award (2014) and the Hong Kong College of Physicians Young Investigators’ Award (2014). He also led the team who won the International Association for the Study of Lung Cancer (IASLC) Foundation Cancer Care Team Award in recognition for providing the best thoracic oncology care in the ’Asia & Rest of the World’ category (2018).

Dr. Loong has co-founded the Asia Pacific Oncology Drug Development Consortium (APODDC) and the Asia Pacific Coalition Against Lung Cancer (APCLC). He also serves on a range of international professional oncology bodies, such as the International Affairs Committee and the Asia Pacific Regional Council of ASCO; the Membership, Education and Communications committees of IASLC; and the Connective Tissue Oncology Society.

He is a board member in the specialty of medical oncology in the Hong Kong College of Physicians. As a member of the Registration Committee for the Pharmacy and Poisons Board of Hong Kong, Dr. Loong helps oversee the registration of medicinal products and clinical trials in the territory.

Most Representative Publications

1. Zhou C, Solomon B, Loong, HH, Park K, Pérol M, Arriola E, Novello S, Han B, Zhou J, Ardizzoni A, Mak MP, Santini FC, Elamin YY, Drilon A, Wolf J, Payakachat N, Uh MK, Rajakumar D, Han H, Puri T, Soldatenkova V, Lin AB, Lin BK, Goto K; LIBRETTO-431 Trial Investigators. First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC. N Engl J Med. 2023; 389:1839-1850.
2. Drilon A, Subbiah V, Gautschi O, Tomasini P, de Braud F, Solomon BJ, Shao-Weng Tan D, Alonso G, Wolf J, Park K, Goto K, Soldatenkova V, Szymczak S, Barker SS, Puri T, Bence Lin A, Loong, HH, Besse B. Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial. J Clin Oncol. 2023; 41:385-394.
3. Mok FST, Tong M, Loong, HH, Mok TSK. Local ablative radiotherapy on oligo-progression while continued on epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer patients: A longer cohort. Asia Pac J Clin Oncol. 2022;18: 614-624.
4. Subbiah V, Gainor JF, Oxnard GR, Tan DSW, Owen DH, Cho BC, Loong, HH, McCoach CE, Weiss J, Kim YJ, Bazhenova L, Park K, Daga H, Besse B, Gautschi O, Rolfo C, Zhu EY, Kherani JF, Huang X, Kang S, Drilon A. Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial. Clin Cancer Res. 2021; 27:4160-4167.
5. Loong, HH, Du N, Cheng C, Lin H, Guo J, Lin G, Li M, Jiang T, Shi Z, Cui Y, Jin X, Yao J, Xing Y, Yao M, Wang K, Mok TSK, Liu L. KRAS G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples. Transl Lung Cancer Res. 2020; 9:1759-1769.
6. Loong, HH, Wong AM, Chan DT, Cheung MS, Chow C, Ding X, Chan AK, Johnston PA, Lau JY, Poon WS, Wong N. Patient-derived tumor organoid predicts drugs response in glioblastoma: A step forward in personalized cancer therapy? J Clin Neurosci. 2020; 78:400-402.
7. Loong, HH, Wong CKH, Leung LKS, Dhankhar P, Insinga RP, Chandwani S, Hsu DC, Lee MYK, Huang M, Pellissier J, Rai A, Achra M, Tan SC. Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong. Pharmacoecon Open. 2020; 4:235-247.
8. Felip E, de Braud FG, Maur M, Loong, HH, Shaw AT, Vansteenkiste JF, John T, Liu G, Lolkema MP, Selvaggi G, Giannone V, Cazorla P, Baum J, Balbin OA, Wang LV, Lau YY, Scott JW, Tan DS. Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non-Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study. J Thorac Oncol. 2020; 15:392-403.
9. Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong, HH, Buchschacher GL Jr, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD; trial investigators. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020; 21:271-282
10. Loong, HH, Kwan SS, Mok TS, Lau YM. Therapeutic Strategies in EGFR Mutant Non-Small Cell Lung Cancer. Curr Treat Options Oncol. 2018; 19:58.
11. Tong CWS, Wu WKK, Loong, HH, Cho WCS, To KKW. Drug combination approach to overcome resistance to EGFR tyrosine kinase inhibitors in lung cancer. Cancer Lett. 2017; 405:100-110.
12. Choy CT, Wong CH, Loong, HH. Low expressions of ASS1 and OTC in glioblastoma suggest the potential clinical use of recombinant human arginase (rhArg). J Neurooncol. 2016; 129: 579-581.
13. Loong, HH, Mok K, Leung LK, Mok TS. Crizotinib in the management of advanced-stage non-small-cell lung cancer. Future Oncol. 2015; 11: 735-745.
14. Loong HH, Yeo W. Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma. Onco Targets Ther. 2014; 7: 575-585.